Jefferies Financial Group Inc. Sells 18,615 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Jefferies Financial Group Inc. cut its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 53.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,000 shares of the pharmaceutical company’s stock after selling 18,615 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Vertex Pharmaceuticals were worth $6,266,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Police & Firemen s Retirement System of New Jersey grew its holdings in Vertex Pharmaceuticals by 3.7% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 39,035 shares of the pharmaceutical company’s stock worth $17,378,000 after buying an additional 1,393 shares in the last quarter. Bailard Inc. raised its position in Vertex Pharmaceuticals by 0.5% in the second quarter. Bailard Inc. now owns 38,147 shares of the pharmaceutical company’s stock worth $16,983,000 after acquiring an additional 200 shares during the period. Leuthold Group LLC bought a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter worth approximately $5,030,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Vertex Pharmaceuticals by 3.8% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 544,978 shares of the pharmaceutical company’s stock valued at $213,435,000 after buying an additional 20,053 shares during the last quarter. Finally, Advisory Resource Group purchased a new stake in Vertex Pharmaceuticals during the third quarter valued at about $1,286,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Activity at Vertex Pharmaceuticals

In related news, EVP Charles F. Wagner, Jr. sold 9,532 shares of the company’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $461.00, for a total value of $4,394,252.00. Following the completion of the transaction, the executive vice president owned 37,725 shares of the company’s stock, valued at approximately $17,391,225. This represents a 20.17% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Mark E. Bunnage sold 2,021 shares of the firm’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $460.43, for a total value of $930,529.03. Following the sale, the executive vice president directly owned 12,914 shares in the company, valued at approximately $5,945,993.02. This represents a 13.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 91,156 shares of company stock worth $42,845,497 in the last 90 days. Company insiders own 0.20% of the company’s stock.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: RAINIER interim results: The company said a pre‑specified Week‑36 interim analysis of the Phase 3 RAINIER trial of povetacicept met the primary objective and all secondary endpoints, citing meaningful efficacy vs. placebo in adults with IgA nephropathy — the core catalyst driving the move. Business Wire release
• Positive Sentiment: Analyst reinforcement: William Blair’s Myles Minter reiterated a Buy and said confidence in povetacicept’s profile has increased after the RAINIER readout, strengthening the bullish investment case for VRTX. Analyst backing amplifies the positive reaction. TipRanks/William Blair note
• Positive Sentiment: Perception of high commercial potential: Coverage notes that povetacicept — acquired in a multibillion‑dollar deal — could be a best‑in‑class therapy in a competitive kidney disease market, supporting a longer‑term revenue upside if full data and approvals follow. BioPharmaDive article
• Neutral Sentiment: Market reaction and headlines: Media and trading outlets reported a sharp after‑hours/share surge following the announcement; that immediate momentum reflects sentiment but may be volatile as investors digest details and next steps. Benzinga coverage
• Negative Sentiment: Ongoing uncertainty: These are interim results from an ongoing trial — final RAINIER readout, safety follow‑up, regulatory timelines and payer/commercial execution remain unknown. Investors should weigh upside against the risk that final data or regulatory review could change the outlook. Yahoo Finance release

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock opened at $460.87 on Tuesday. The stock has a fifty day moving average of $467.50 and a 200 day moving average of $435.79. The stock has a market cap of $117.07 billion, a PE ratio of 30.06 and a beta of 0.31. Vertex Pharmaceuticals Incorporated has a one year low of $362.50 and a one year high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). The company had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.18 billion. Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The business’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.98 EPS. As a group, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Oppenheimer upgraded Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $540.00 target price for the company in a research note on Friday, February 13th. HC Wainwright set a $591.00 target price on Vertex Pharmaceuticals in a research report on Tuesday, February 17th. Wells Fargo & Company upped their price target on shares of Vertex Pharmaceuticals from $460.00 to $515.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. Canaccord Genuity Group raised their target price on shares of Vertex Pharmaceuticals from $411.00 to $441.00 and gave the stock a “hold” rating in a report on Tuesday, February 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $590.00 target price on shares of Vertex Pharmaceuticals in a research note on Friday, February 13th. Twenty-two investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $542.00.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.